Skip Navigation LinksHome > February 27, 2014 - Volume 97 - Issue 4 > Acute Cellular Rejection: Impact of Donor-Specific Antibodie...
doi: 10.1097/01.TP.0000437431.97108.8f
Clinical and Translational Research

Acute Cellular Rejection: Impact of Donor-Specific Antibodies and C4d

Willicombe, Michelle1,5; Roufosse, Candice2; Brookes, Paul3; McLean, Adam G.1; Galliford, Jack1; Cairns, Tom1; Cook, Terry H.4; Taube, David1

Supplemental Author Material
Collapse Box



Mixed rejection in kidney transplantation consists of histologic and/or serological evidence of both cellular and humoral components. As it is not confined to a distinct category in the Banff classification, how to best manage these patients is not clear. The aim of this study was to determine the incidence and outcome of morphological T-cell–mediated rejection (TCMR) with a humoral component, defined as the presence of either DSA or C4d, compared with the outcome of pure TCMR.


We retrospectively studied 922 consecutive renal transplant recipients and analyzed patients with TCMR according to the evidence of a humoral component.


A total of 147 cases of morphological TCMR were analyzed. Of these, 92 (62.6%) had “pure” TCMR and 55 (37.4%) had “mixed” TCMR on the index biopsy. On univariant analysis, diffuse C4d (odds ratio [OR]=10.9, 95% confidence interval [CI]=1.8–66.9, P=0.01) and DSA positivity at the time of index biopsy (OR=2.8, 95% CI=1.2–6.6, P=0.02) were associated with allograft loss, whereas arteritis (OR=0.5, 95% CI=0.2–1.2, P=0.11) and glomerulitis (OR=0.9, 95% CI=0.4–2.1, P=0.8) were not. Arteritis was associated with subsequent antibody-mediated rejection (OR=4.9, 95% CI=1.1–20.8, P=0.03), and glomerulitis was associated with the development of transplant glomerulopathy (OR=10.7, 95% CI=3.1–37.1, P<0.01). On the multivariate analysis, only patients with C4d and DSA were at risk of graft failure (OR=4.9, 95% CI=2.0–12.0, P<0.01) in the medium term.


TCMR with a humoral component has a worse prognosis when compared with pure TCMR. As such, it is important to test for alloantibody in cases of morphological TCMR to optimize patient management. Such cases might benefit from more aggressive immunotherapy.

Copyright © 2014 by Lippincott Williams & Wilkins


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.